Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback